Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:canBe |
pain management
neurological disorders |
| gptkbp:CASNumber |
1071513-28-6
|
| gptkbp:developedBy |
gptkb:Pfizer
|
| gptkbp:drugClass |
gptkb:enzyme
|
| gptkbp:hasInChIKey |
QJQYQKZQZJYQJQ-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C23H20F3N3O3
|
| gptkbp:hasSMILES |
C1CN(CCC1OCc2cccc(c2)C(F)(F)F)C(=O)Nc3cccnc3
|
| https://www.w3.org/2000/01/rdf-schema#label |
PF-04457845
|
| gptkbp:isA |
fatty acid amide hydrolase inhibitor
|
| gptkbp:IUPACName |
N-pyridin-3-yl-4-[[3-(trifluoromethyl)phenyl]methyl]oxypiperidine-1-carboxamide
|
| gptkbp:molecularWeight |
443.42 g/mol
|
| gptkbp:PubChem_CID |
25154816
CHEMBL2103887 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
PF04457845
N-pyridin-3-yl-4-[[3-(trifluoromethyl)phenyl]methyl]oxypiperidine-1-carboxamide |
| gptkbp:target |
gptkb:fatty_acid_amide_hydrolase
|
| gptkbp:usedIn |
research
|
| gptkbp:bfsParent |
gptkb:486460-32-6
gptkb:641571-10-0 |
| gptkbp:bfsLayer |
6
|